Every 8-K that Carlsmed, Inc. (CARL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CARL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CARL filings page.
Carlsmed, Inc. (CARL) announced that its Board of Directors appointed Jeffrey (Jeff) Bertolini as Chief Operating Officer, effective September 8, 2026. He has held senior operations roles at Carlsmed since 2024 and previously at SI-BONE, NuVasive, and US Surgical.
Bertolini’s employment agreement includes a base salary that increases to $475,000 with a 60% target annual cash incentive opportunity. If his employment is terminated without cause or he resigns for good reason outside of a defined corporate-transaction window, he is eligible for 12 months of base-salary continuation, potential annual incentive payments, and up to 12 months of COBRA reimbursements. On September 8, 2026, he was also granted 50,000 stock options to purchase Carlsmed common stock.
Carlsmed, Inc. reported strong growth for the quarter ended June 30, 2026, with revenue of $18.9 million, up 57% from $12.1 million a year earlier, driven by increasing adoption of its AI-enabled aprevo spine surgery solutions. Gross profit rose to $14.5 million and gross margin expanded to 76.8% from 73.4%, while trained surgeon users grew more than 60% year-over-year. The company highlighted growing volume across lumbar and cervical procedures, with aprevo cervical in its second full quarter of commercialization and contributing about 10% of quarterly revenue.
Operating expenses increased to $25.6 million from $15.4 million as Carlsmed invested in research and development, sales and marketing, and administrative capabilities, leading to a net loss of $10.5 million versus $6.8 million last year and adjusted EBITDA of ($8.6 million). Cash, restricted cash, short-term investments, and marketable securities totaled $89.3 million as of June 30, 2026. Management raised full‑year 2026 revenue guidance to a range of $74–$78 million, representing over 50% growth at the midpoint versus 2025 and slightly above the prior $72–$77 million range. The company also cited a recent CMS Inpatient Prospective Payment System ruling, effective October 1, 2026, that adds new MS‑DRG codes and provides favorable hospital reimbursement for inpatient aprevo lumbar procedures.
Carlsmed, Inc. held its 2026 Annual Meeting of Stockholders on June 3, 2026, where stockholders voted on director elections and auditor ratification. Niall Casey and Philip Young were elected as Class I directors to serve until the 2029 annual meeting or until successors are elected and qualified.
Casey received 19,627,716 votes for and 1,352,117 votes withheld, while Young received 19,510,686 votes for and 1,469,147 votes withheld, with 4,628,080 broker non-votes on each director proposal. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 25,571,065 votes for, 5,858 against, and 30,990 abstentions.
Carlsmed, Inc. reported strong first quarter 2026 results, with revenue of $16.1 million, up 58.2% from $10.2 million a year earlier. Gross profit rose to $12.4 million and gross margin improved to 77.1% from 74.9%.
The company posted a net loss of $8.7 million and adjusted EBITDA of -$7.5 million, both larger losses than in 2025 as it increased spending on research and development, sales and marketing, and general and administrative activities. Cash, restricted cash, and short-term investments totaled $97.1 million as of March 31, 2026.
Carlsmed raised its full-year 2026 revenue outlook to $72–$77 million, implying about 48% growth at the midpoint over 2025. The company highlighted new clinical data showing reduced revision surgeries for its aprevo personalized implants and initial procedures with its corra personalized fixation portfolio.
Carlsmed, Inc. reported rapid growth in its AI-enabled spine surgery business for 2025, with revenue rising to $50.5 million, an 86% increase from 2024. Fourth quarter revenue reached $15.2 million, up 61% year over year, while gross margin improved to 76.5%, showing strong unit economics.
Growth is being driven by new products like the aprevo® cervical system, the myaprevo® ecosystem, and first-in-human procedures for personalized spine implants. Operating expenses increased to $68.6 million in 2025 as the company invested in R&D and sales, resulting in a net loss of $29.6 million and Adjusted EBITDA loss of $28.4 million.
Carlsmed ended 2025 with $109.9 million in cash, restricted cash, and short-term investments, providing funding for continued expansion. For 2026, it expects revenue between $70 million and $75 million, implying about 44% growth at the midpoint over 2025.
Carlsmed, Inc. filed a current report to disclose that it has issued a press release announcing its preliminary, unaudited revenue for the year ended December 31, 2025. The company furnished the full text of this press release as Exhibit 99.1, stating that it is incorporated by reference in the report but will not be treated as filed for liability purposes under the Exchange Act. The filing also notes that Carlsmed’s common stock trades on The Nasdaq Stock Market LLC under the symbol CARL.
Carlsmed, Inc. furnished an update on its latest performance. The company announced financial results for the quarter ended September 30, 2025, via a press release furnished with a Form 8-K.
The press release is included as Exhibit 99.1. The information furnished under Item 2.02 is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference into Securities Act filings except as specifically referenced.
Carlsmed, Inc. amended its loan agreement with Customers Bank, adding a credit facility consisting of a Term Loan of up to $50.0 million and a $10.0 million non‑formula revolver, with total advances capped at $50.0 million. Of the Term Loan, $17.5 million is contingent on revenue milestones. The interest rate is the greater of WSJ Prime + 0.25% or 5.25%, which was 7.50% as of September 30, 2025.
The Term Loan matures on October 15, 2030 with interest‑only through October 15, 2027, extendable to October 15, 2028 upon milestone achievement. The revolver matures on October 15, 2028. The company must keep at least $20.0 million in an operating account at Customers Bank and meet minimum revenue thresholds if deposits are less than 100% of outstanding debt.
Carlsmed also reduced warrant overhang tied to future draws: the Series B warrant decreased from 58,420 to 52,776 shares, and the Series C from 20,375 to 10,188, cancelling contingent rights to 15,831 shares in total.
Carlsmed, Inc. filed a current report to disclose that it has released its financial results for the quarter ended June 30, 2025. On August 28, 2025, the company issued a press release with these quarterly results, which is included as Exhibit 99.1 to the report.
The press release describing the quarter’s results is being furnished rather than filed, meaning it is not automatically subject to certain liability provisions and is not automatically incorporated into other securities filings unless specifically referenced. The company’s common stock, with a par value of $0.00001 per share, trades on The Nasdaq Stock Market LLC under the symbol CARL.